Develops vaccine candidates to prevent bacterial diseases in adults and children, using a way to make vaccine proteins without cells.
10-K for FY2025, filed Feb 24, 2026
No revenue reported yet.
10-K for FY2025, filed Feb 24, 2026
10-Q for Q3 FY2026, filed Nov 4, 2026
−$297.1MView ↗
Pipeline emphasis
The pneumococcal program's emphasis has moved from the candidate described as the lead in the older report to a different candidate advancing in adult pivotal trials; the earlier lead is being studied in infants.
10-K for FY2022, filed Feb 27, 2023Our lead vaccine candidate, VAX-24, is a 24-valent, broad-spectrum investigational PCV being developed for the prevention of IPD. VAX-24 is…View ↗
Competes with Pfizer, Merck, GSK, Sanofi, Moderna, VaxForm, BioMVis, Valneva, LimmaTech, and SK bioscience
10-K for FY2025, filed Feb 24, 2026Within the current pneumococcal vaccine market, Pfizer, Merck and GSK have comprised the significant majority of market share and sales…View ↗
Loading...